Metastatic castration-resistant prostate cancer patients
Clinical trials for Metastatic castration-resistant prostate cancer patients explained in plain language.
Never miss a new study
Get alerted when new Metastatic castration-resistant prostate cancer patients trials appear
Sign up with your email to follow new studies for Metastatic castration-resistant prostate cancer patients, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo targets prostate cancer that outsmarts hormone therapy
Disease control Recruiting nowResearchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase 1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase 1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill shows promise against resistant cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase 1 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC